Barclays
PRCT icon

Barclays’s Procept Biorobotics PRCT Stock Holding History

Barclays’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.69M Buy
163,356
+30,869
+23% +$773K ﹤0.01% 2005
2026
Q1 		$3.31M Buy
132,487
+36,158
+38% +$1.02M ﹤0.01% 2063
2025
Q4 		$3.03M Buy
96,329
+18,658
+24% +$619K ﹤0.01% 2632
2025
Q3 		$2.77M Sell
77,671
-47,583
-38% -$2.17M ﹤0.01% 2622
2025
Q2 		$7.21M Buy
125,254
+65,328
+109% +$3.69M ﹤0.01% 1810
2025
Q1 		$3.49M Sell
59,926
-96,931
-62% -$6.62M ﹤0.01% 2197
2024
Q4 		$12.6M Buy
156,857
+78,923
+101% +$6.74M ﹤0.01% 1394
2024
Q3 		$6.24M Buy
77,934
+62,599
+408% +$4.45M ﹤0.01% 1885
2024
Q2 		$937K Sell
15,335
-22,241
-59% -$1.32M ﹤0.01% 2641
2024
Q1 		$1.86M Sell
37,576
-26,813
-42% -$1.28M ﹤0.01% 2634
2023
Q4 		$2.7M Buy
64,389
+12,776
+25% +$435K ﹤0.01% 2666
2023
Q3 		$1.69M Buy
51,613
+35,746
+225% +$1.22M ﹤0.01% 1995
2023
Q2 		$561K Buy
15,867
+2,659
+20% +$87.9K ﹤0.01% 2680
2023
Q1 		$375K Buy
13,208
+6,248
+90% +$220K ﹤0.01% 3457
2022
Q4 		$289K Buy
6,960
+5,875
+541% +$252K ﹤0.01% 3647
2022
Q3 		$45K Sell
1,085
-200
-16% -$7.98K ﹤0.01% 3811
2022
Q2 		$42K Buy
1,285
+110
+9% +$4K ﹤0.01% 4099
2022
Q1 		$41K Buy
+1,175
New +$28.3K ﹤0.01% 4195

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Barclays's PRCT Position: Q2 2026 in Review

Barclays increased its Procept Biorobotics (PRCT) stake by 23% in Q2 2026, buying an estimated $773K and bringing the position to 163,356 shares worth $3.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2005.

Barclays first reported a position in PRCT in Q1 2022 and has held it in 18 quarters since. The position peaked at $12.6M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Barclays held 163,356 shares of Procept Biorobotics worth $3.69M as of Q2 2026.
  • Barclays bought 30,869 Procept Biorobotics shares in Q2 2026, an estimated $773K.
  • Procept Biorobotics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2005 holding.
  • Barclays first reported a position in Procept Biorobotics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Procept Biorobotics position peaked at $12.6M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.